الفهرس 
Title : Hepatic arterial chemoperfusion in treatment of advanced hepatocellular carcinoma with portal vein thrombosis
ContentsOnly 14 pages are availabe for public view
 |  | from | 135 |  |  |
| | | from | 135 | | |
Abstract
orafenib, the multi-kinase inhibitor, is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT) according to EASL guidelines. Other guidelines as the Japanese and Korean recommended hepatic arterial infusion chemotherapy (HAIC) as first line for patients with PVTT followed by Sorafenib as second line and keeping Sorafenib as first line for advanced HCC without PVTT. Aim of work: The aim of this study is to describe the treatment efficacy and survival benefits of HAIC for patients with advanced HCC and PVTT, BCLC-C with compensated cirrhosis (Child-Pugh A) in comparison with Sorafenib as standard of care therapy for such patients versus Best Supportive Care (BSC). Patients and methods: This study included ninety one patients with advanced HCC and PVTT who were recruited from multidisciplinary HCC clinic, Kasr-Alainy, in the period fromApril 2016 till June 2017.Patients were divided into three groups: group 1: 20 treated with HAIC, The patients received arterial infusion of chemotherapeutic agents in the form of 50 mg Adriamycin and 50 mg Cisplatin.group 2:42 patients were treated with BSC and group 3: 29 patients were treated with Sorafenib. The dose of sorafenib was adjusted according to adverse events. Patients were followed up for assessment and comparison of treatment outcome by modified RECIST criteriaand survival